The situation for AbbVie probably isn't nearly as bad as you think it is.
News & Analysis: AbbVie
These stocks provide dependable high dividend yields along with solid growth prospects.
AbbVie failed big-time with its decision to buy Stemcentrx to get Rova-T. Here's what investors can learn from its mistake.
Low valuations, high prices: These three stocks appear to be ready to put in your shopping cart right now.
Which stock wins in a battle between these two big pharma companies?
The FDA just gave a thumbs-up to rheumatoid arthritis drug Rinvoq. It could become AbbVie's biggest immunology blockbuster after Humira.
FDA approvals for these drugs could translate to billions of dollars for a few companies.
Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.
And the one big pharma most likely to benefit the most.
High yields. Low valuations. But with a couple of downsides to be aware of.